266 related articles for article (PubMed ID: 33711994)
1. The impact of early phase price agreements on prices of orphan drugs.
Nuijten M; Van Wilder P
BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
[TBL] [Abstract][Full Text] [Related]
2. An integrated valuation model for payer and investor.
Nuijten M; Capri S
J Mark Access Health Policy; 2022; 10(1):2080631. PubMed ID: 35693380
[TBL] [Abstract][Full Text] [Related]
3. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
4. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands.
Hagendijk ME; van der Schans S; Boersma C; Postma MJ; van der Pol S
Eur J Health Econ; 2021 Aug; 22(6):991-999. PubMed ID: 33829344
[TBL] [Abstract][Full Text] [Related]
6. Pricing of orphan drugs in oncology and rare diseases.
Nuijten M; Capri S
J Mark Access Health Policy; 2020 Dec; 8(1):1838191. PubMed ID: 33312455
[No Abstract] [Full Text] [Related]
7. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
8. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
9. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
10. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
Wettstein DJ; Boes S
BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
[TBL] [Abstract][Full Text] [Related]
11. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
Kawakami A; Masamune K
Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
[TBL] [Abstract][Full Text] [Related]
12. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
13. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
14. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
Picavet E; Cassiman D; Simoens S
J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
[TBL] [Abstract][Full Text] [Related]
15. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
16. Shining a light in the black box of orphan drug pricing.
Picavet E; Morel T; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Apr; 9():62. PubMed ID: 24767472
[TBL] [Abstract][Full Text] [Related]
17. Establishing a reasonable price for an orphan drug.
Berdud M; Drummond M; Towse A
Cost Eff Resour Alloc; 2020; 18():31. PubMed ID: 32908456
[TBL] [Abstract][Full Text] [Related]
18. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.
Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399
[TBL] [Abstract][Full Text] [Related]
19. The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach.
Capri S; Antoñanzas F; Levaggi R
Expert Rev Pharmacoecon Outcomes Res; 2023 Apr; 23(4):431-438. PubMed ID: 36823030
[TBL] [Abstract][Full Text] [Related]
20. Variables affecting pricing of orphan drugs: the Italian case.
Jommi C; Listorti E; Villa F; Ghislandi S; Genazzani A; Cangini A; Trotta F
Orphanet J Rare Dis; 2021 Oct; 16(1):439. PubMed ID: 34666819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
